EE524 Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab for High-Risk Early-Stage Triple Negative Breast Cancer in Costa Rica

The objective of the model was to evaluate the cost-effectiveness of neoadjuvant pembrolizumab + chemotherapy followed by adjuvant pembrolizumab after surgery in patients with high-risk early-stage triple negative breast cancer (TNBC) in Costa Rica.

Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: A.M. Rendon, R. Cordoba, V. Wurcel, R. Rubino, M. Junqueira, A. Haiderali, M. Huang, A. Khandelwal, S. Gotarkar Source Type: research